Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.
IPO Year: 2021
Exchange: NASDAQ
Website: https://www.bionomics.com.au
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/28/2023 | $7.00 → $10.00 | Buy | Maxim Group |
| 9/28/2023 | $8.00 | Neutral → Buy | H.C. Wainwright |
| 1/10/2022 | $54.00 | Buy | H.C. Wainwright |
| 1/10/2022 | $52.00 | Overweight | Cantor Fitzgerald |
| 1/10/2022 | $17.00 | Outperform | Evercore ISI Group |
| 1/10/2022 | $21.00 | Buy | Berenberg |
ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company) is pleased to announce that the Supreme Court of New South Wales, Australia ("Court") has today made orders approving the scheme of arrangement in relation to the Company's proposed re-domiciliation from Australia to the United States ("Scheme"), under which Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria"), will become the ultimate parent company of Bionomics Limited following the implementation of the Scheme. A copy of the Court's orders with respect to the Scheme was lodged with the Australian Securities & Investments Commission following t
ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) ("Bionomics" or the "Company") is pleased to provide the following update on the status of its proposed re-domiciliation from Australia to the United States. Bionomics shareholders have today approved, by the requisite majority, the proposed Scheme of Arrangement in relation to the Company's proposed re-domiciliation from Australia to the United States, under which Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria"), will become the ultimate parent company of Bionomics Limited following the implementation of the Scheme of Arrangement. Voting Results In summary: 96%
BNC210 improved PTSD symptom severity at Week 12 with efficacy observed as early as Week 4Company plans to initiate a Phase 3 study of BNC210 in PTSD in H2 2025 ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that the positive results from its Phase 2 ATTUNE study have been published in the NEJM Evidence. The data were also presented yesterday at the 63ʳᵈ Annual Meeting of the
ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be giving oral presentation on the results of the Phase 2 ATTUNE trial of BNC210 in post-traumatic stress disorder in the inaugural "Promising Targets" session at the 63ʳᵈ Annual Meeting of the American College of Neuropsychopharmacology (ACNP) being held December 8-11, 2024 in Phoenix, AZ. Oral Presentation Details:
ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, is reminding Shareholders to cast their vote in favor of the Scheme Implementation Agreement to re-domicile Bionomics from Australia to the U.S. "The re-domiciliation of Bionomics through the Scheme is key for our ability to execute our strategic vision and set the Company for success. I'd like to highlight that voting in favor of the Scheme was
ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provides an update to the proposed re-domiciliation of Bionomics to the United States by way of scheme of arrangement between Bionomics and its Shareholders ("Scheme") as announced on 1 October 2024. Shareholders of Bionomics will receive a proportionate number of shares of common stock in Neuphoria Therapeutics Inc. ("Neuphoria"), a new
ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be participating and presenting at the 15th CNS Summit being held November 10-13, 2024 at the Encore Boston Hotel in Boston, MA. Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics, will deliver a company presentation during the Neuroscience Spotlight session taking place on Tuesday, November 12
ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it received a milestone payment of AUS$1M from Carina Biotech for BNC101, one of their partnered legacy oncology programs. On October 30, 2024, Carina Biotech, a clinical-stage immuno-oncology company developing CAR-T and other cell therapies for the treatment of solid cancers, made a milestone payment of AUS$1M to Bionomics.
ADELAIDE, Australia and CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be participating and presenting at the ThinkEquity Conference being held October 30, 2024 at the Mandarin Oriental Hotel in New York, NY. Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics, will deliver a company presentation on October 30 at 1:30 p.m. ET in the Lotus Suite West. A live webcast of the
ADELAIDE, Australia and CAMBRIDGE, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that the Company has been invited to present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, starting Tuesday, October 15th, 2024, at 9:00 a.m. E.T. Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics, will participate in a fireside chat with Maxim's Senior Analysts on Wednesday,
3 - BIONOMICS LIMITED/FI (0001191070) (Issuer)
3 - BIONOMICS LIMITED/FI (0001191070) (Issuer)
3 - BIONOMICS LIMITED/FI (0001191070) (Issuer)
3 - BIONOMICS LIMITED/FI (0001191070) (Issuer)
3 - BIONOMICS LIMITED/FI (0001191070) (Issuer)
3 - BIONOMICS LIMITED/FI (0001191070) (Issuer)
3 - BIONOMICS LIMITED/FI (0001191070) (Issuer)
Alan Fisher appointed Chair of the Board of DirectorsTim Cunningham joins as Chief Financial Officer ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth. Alan Fisher, currently a non-executive me
ADELAIDE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited ((ASX: BNO, NASDAQ:BNOX), today announced its FY2023 report for the half-year ended 31 December 2022. This period represented a transformational time for Bionomics in which the Company made great strides on multiple fronts, including progress on advancing the pipeline, raising capital, and implementing strategic corporate initiatives designed to create long-term shareholder value. The Company recently completed its Phase 2 PREVAIL Study to evaluate BNC210 for the acute treatment of Social Anxiety Disorder (SAD). The PREVAIL Study, initiated in January 2022, was a randomised, double-blind, placebo-controlled, multi-ce
ADELAIDE, Australia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it has appointed Spyridon "Spyros" Papapetropoulos, M.D. as President and Chief Executive Officer (CEO), effective 5 January 2023. Errol B. De Souza, Ph.D., who has been serving as Bionomics' Executive Chairman since November 2018, will continue in his role through 31 December 2022 to ensure a seamless transition, and
Maxim Group reiterated coverage of Bionomics Limited with a rating of Buy and set a new price target of $10.00 from $7.00 previously
H.C. Wainwright upgraded Bionomics Limited from Neutral to Buy and set a new price target of $8.00
H.C. Wainwright initiated coverage of Bionomics Limited with a rating of Buy and set a new price target of $54.00
Cantor Fitzgerald initiated coverage of Bionomics Limited with a rating of Overweight and set a new price target of $52.00
Evercore ISI Group initiated coverage of Bionomics with a rating of Outperform and set a new price target of $17.00
Berenberg initiated coverage of Bionomics with a rating of Buy and set a new price target of $21.00
Successful End-of-Phase 2 (EoP2) meeting with U.S. Food and Drug Administration (FDA) provides a potential path to New Drug Application (NDA) submission for BNC210 for post-traumatic stress disorder (PTSD) with a single Phase 3 trialCompany received favorable FDA feedback on the Phase 3 study design and safety monitoring plans required for registrationCompany plans to initiate the Phase 3 program in Q4 2024A conference call and webcast presentation to discuss the outcomes will be held today at 8:00 a.m. ET, details below ADELAIDE, Australia and CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology com
ADELAIDE, Australia and CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will provide a corporate update and discuss the outcomes of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration regarding the advancement of BNC210 for the treatment of post-traumatic stress disorder (PTSD) into Phase 3 on Wednesday, July 31 at 8:00 am ET. Conference Call and Webcast PresentationDat
ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints showed improvements in depressive symptoms and sleep. BNC210 was well-tolerated with a safety profile supporting chronic administration. Company plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the registrational path for BNC210 in PTSD. Webcast and conference call will be held today at 8:00 AM EST (10:00 PM AEST). Please click on the link to register: https://lifescievents.com/event/bnox/ ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE)
ADELAIDE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO, ))), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today released its Appendix 4C – Quarterly Cashflow Report. Highlights during the Quarter ended 31 March 2023 (Quarter) and up to the date of this announcement include: On 1 January 2023, Errol B. De Souza, Ph.D., assumed the role of Non-Executive Chairman of the Board of Directors. Dr. De Souza had previously served as Bionomics' Exe
Both doses of BNC210 as an acute treatment resulted in reductions in anxiety across multiple phases of the public speaking challengeResults achieved statistical significance in post-hoc analysis of the full data set and in relevant subpopulations Favourable safety, tolerability and PK findings are consistent with a fast-acting non-sedating anxiolytic profileThe company is planning an End of Phase 2 (EoPh2) meeting to discuss BNC210's late-stage SAD program 2H 2023 Webcast and conference call scheduled for Thursday, March 9, 2023 at 8:00 AM EST (Friday, March 10, 2023 at 12:00 AM AEDT) ADELAIDE, Australia, March 08, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))) (Bi
ADELAIDE, Australia, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited ((ASX:BNO, NASDAQ:BNOX), today announced its financial results for the 12 months ended 30 June 2022. Bionomics is a clinical stage biopharmaceutical company developing novel, allosteric, ion channel modulators designed to transform the lives of patients suffering from serious CNS disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral proprietary selective Negative Allosteric Modulator of the 7 nicotinic acetylcholine receptor ("7 receptor") for the acute treatment of Social Anxiety Disorder ("SAD") and chronic treatment of Post-Traumatic Stress Disorder ("PTSD"). D
SC 13G - BIONOMICS LIMITED/FI (0001191070) (Subject)
SC 13G/A - BIONOMICS LIMITED/FI (0001191070) (Subject)
SC 13D/A - BIONOMICS LIMITED/FI (0001191070) (Subject)
SC 13G/A - BIONOMICS LIMITED/FI (0001191070) (Subject)
SC 13G/A - BIONOMICS LIMITED/FI (0001191070) (Subject)
SC 13G/A - BIONOMICS LIMITED/FI (0001191070) (Subject)
SC 13G/A - BIONOMICS LIMITED/FI (0001191070) (Subject)
SC 13G - BIONOMICS LIMITED/FI (0001191070) (Subject)
SC 13G - BIONOMICS LIMITED/FI (0001191070) (Subject)
SC 13G - BIONOMICS LIMITED/FI (0001191070) (Subject)
S-3/A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
EFFECT - Neuphoria Therapeutics Inc. (0001191070) (Filer)
EFFECT - Neuphoria Therapeutics Inc. (0001191070) (Filer)
8-K - BIONOMICS LIMITED/FI (0001191070) (Filer)
POS AM - BIONOMICS LIMITED/FI (0001191070) (Filer)
POS AM - BIONOMICS LIMITED/FI (0001191070) (Filer)
15-12G - BIONOMICS LIMITED/FI (0001191070) (Filer)
8-K - BIONOMICS LIMITED/FI (0001191070) (Filer)
8-K - BIONOMICS LIMITED/FI (0001191070) (Filer)
S-3/A - BIONOMICS LIMITED/FI (0001191070) (Filer)